{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:37:01Z","timestamp":1775065021586,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ymthe.2025.12.039","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:05:44Z","timestamp":1766592344000},"page":"1997-2011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous administration of EXG110 resulted in substrate correction in Fabry mice and sustained enzyme activity in non-human primates"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-3532","authenticated-orcid":false,"given":"Shaoyong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingzeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongwan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chentao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan Yue","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Song","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yigang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1158-2877","authenticated-orcid":false,"given":"Zhenhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.12.039_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.039_bib2","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1093\/nar\/17.8.3301","article-title":"Nucleotide sequence of the human alpha-galactosidase A gene","volume":"17","author":"Kornreich","year":"1989","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.12.039_bib3","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.ymthe.2025.12.039_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101439","article-title":"Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring","volume":"48","author":"Umer","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.ymthe.2025.12.039_bib5","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2025.12.039_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymthe.2025.12.039_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymthe.2025.12.039_bib8","first-page":"95","article-title":"Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2025.12.039_bib9","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.12.039_bib10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.039_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib12","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.12.039_bib13","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.12.039_bib14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.039_bib15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.12.039_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.12.039_bib17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","volume":"30","author":"Jeyakumar","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101375","article-title":"Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease","volume":"32","author":"Liefhebber","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.12.039_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039975","article-title":"Mannose 6-phosphate receptor and sortilin mediated endocytosis of alpha-galactosidase A in kidney endothelial cells","volume":"7","author":"Prabakaran","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.12.039_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.039_bib21","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/mt.2011.119","article-title":"Systemic administration of AAV8-alpha-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression","volume":"19","author":"Nietupski","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/hum.2008.161","article-title":"Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer","volume":"20","author":"Cooper","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib23","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib24","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.ymthe.2024.11.021","article-title":"Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [(18)F]AGAL","volume":"33","author":"Kaittanis","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib25","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.12.039_bib26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/mt.2010.308","article-title":"Transcription factor rational design improves directed differentiation of human mesenchymal stem cells into skeletal myocytes","volume":"19","author":"Goncalves","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib27","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.12.039_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A","volume":"15","author":"Ziegler","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2020.10.016","article-title":"Systemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing alpha-Galactosidase A","volume":"20","author":"Biferi","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.12.039_bib31","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","volume":"42","author":"Greig","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.12.039_bib32","doi-asserted-by":"crossref","first-page":"13777","DOI":"10.1073\/pnas.222221899","article-title":"Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer","volume":"99","author":"Takahashi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.12.039_bib33","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.12.039_bib34","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036815","article-title":"Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down-Regulation of Mannose-6-Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy","volume":"14","author":"Frustaci","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ymthe.2025.12.039_bib36","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/mt.2010.175","article-title":"Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy","volume":"18","author":"Hurlbut","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL\/6J Mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neures.2014.09.002","article-title":"Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex","volume":"93","author":"Watakabe","year":"2015","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ymthe.2025.12.039_bib39","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202113968","article-title":"Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity","volume":"14","author":"Eggers","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2025.12.039_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105617","article-title":"A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors","volume":"14","author":"Davis-Gardner","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.039_bib41","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ymthe.2025.12.039_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.12.039_bib43","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib44","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","article-title":"Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus","volume":"72","author":"Xiao","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.12.039_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/mt.2015.187","article-title":"Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector","volume":"24","author":"Grieger","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/2339702","article-title":"Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation vs. Immuno-Affinity Chromatography","volume":"2023","author":"Lam","year":"2023","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.ymthe.2025.12.039_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625010627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625010627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:34:06Z","timestamp":1775057646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625010627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1525001625010627"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.039","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous administration of EXG110 resulted in substrate correction in Fabry mice and sustained enzyme activity in non-human primates","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}